Refile: BUZZ-Australia's OncoSil Medical rises on cancer device FDA review progress
09/06/2026 04:24
REFILE-BUZZ-Australia's OncoSil Medical rises on cancer device FDA review progress Corrects syntax in headline
** Shares of Australia's OncoSil Medical OSL.AX rise as much as 33.3% to A$0.58, their highest level and biggest intraday pct gain since May 20
** The medical device firm says it received a formal communication from the U.S. FDA confirming that its application for the OncoSil device has reached the final stage of the review process
** OncoSil device is used for the treatment of distal cholangiocarcinoma - rare cancer observed near the small intestine
** Stock down 44.5%, YTD
(Reporting by Aamir Sheik Khalid in Bengaluru)
Recent news on Oncosil Medical
See all newsAustralia's OncoSil Medical gains most in over 2 months on reaching 100-th patient milestone
Brief: Oncosil Medical Says FDA Grants Hde Approval For Oncosil Device For Distal Cholangiocarcinoma
Brief: Oncosil Medical Posts FY26 Unit Sales Up 53%, Revenue Up 44% Versus FY25
Brief: Oncosil Medical Receives Saudi FDA Approval
Brief: Oncosil Medical Files For FDA Approval